Ionis Partners With Metagenomi To Expand Its Genetic Medicines Capabilities
Executive Summary
Ionis will pay $80m up front to Metagenomi to access its next-generation gene-editing technology to jointly research new therapies for up to four genetic targets.
You may also be interested in...
After An Upbeat J.P. Morgan, Three Biopharmas Look To Kick Off IPOs For 2024
Gene editing company Metagenomi and two oncology biopharmas will test the IPO waters soon – with hopes this could pave the way for others.
Ionis Invests For The Future In New Technologies, Manufacturing Innovation
Through partnerships with Bicycle and Metagenomi, Ionis is working on new chemistries and novel medicines. It is also expanding manufacturing capacity to enable its scientific growth.
Finance Watch: VC Round Extensions Attractive While Stock Market Wobbles
Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.